Report
EUR 13.20 For Business Accounts Only

CERUS CORP. sees a downgrade to Negative on account of less fundamental stars

The independent financial analyst theScreener just lowered the general evaluation of CERUS CORP. (US), active in the Biotechnology industry. As regards its fundamental valuation, the title now shows 0 out of 4 stars while market behaviour can be considered risky. theScreener believes that the title remains under pressure due to the loss of a star(s) and downgrades its general evaluation to Negative. As of the analysis date March 15, 2022, the closing price was USD 4.85 and its target price was estimated at USD 4.27.
Underlying
Cerus Corp.

Cerus is a biomedical products company focused on developing and commercializing the INTERCEPT Blood System for blood safety. The INTERCEPT Blood System, which is based on the company's technology for controlling biological replication, is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company's INTERCEPT Blood System is for use with three blood components: plasma, platelets, and red blood cells. The platelet system and plasma system are designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion and the red blood cell system is designed to inactivate blood-borne pathogens in red blood cells donated for transfusion.

Provider
TheScreener
TheScreener

Empowering Investors

theScreener is the market leader for independent valuations of financial securities, equities, sectors and markets, and new funds. theScreener's ratings, analyses are used by leading banks, asset managers and financial portals.  Approximately 10,000 workstations benefit from theScreener's services, with over millions of customer accounts actively analysed.

  • Worldwide coverage: theScreener analyses cover around 6'500 Stocks, i.e 95% of the world Market Capitalization.  theScreener state of art: We provide
  • theScreener state of art: We provide easy to use and complete analyses over Stocks, including Fundamentals / Technical / Risk/ Peer / Alternatives analyses.
  • For Research Pool community, we provide twice a week around 500 new equity analyses. We produce analyses about equities which have been upgraded or downgraded

 

Other Reports on these Companies
Other Reports from TheScreener

ResearchPool Subscriptions

Get the most out of your insights

Get in touch